ZYDUSLIFE Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹947.60 |
| 52 Week High | ₹1,324.30 |
| 52 Week Low | ₹628.10 |
| Beta | 0.43 |
| 11 Month Change | -7.32% |
| 3 Month Change | -21.40% |
| 1 Year Change | 48.28% |
| 33 Year Change | 104.47% |
| 5 Year Change | 270.45% |
| Change since IPO | 10,821.36% |
Recent News & Updates
Recent updates
Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 15
Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching
Sep 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15Shareholder Returns
| ZYDUSLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.2% | -3.1% | -3.4% |
| 1Y | 48.3% | 41.1% | 27.0% |
Return vs Industry: ZYDUSLIFE exceeded the Indian Pharmaceuticals industry which returned 41.1% over the past year.
Return vs Market: ZYDUSLIFE exceeded the Indian Market which returned 27% over the past year.
Price Volatility
| ZYDUSLIFE volatility | |
|---|---|
| ZYDUSLIFE Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ZYDUSLIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ZYDUSLIFE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 26,921 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
| ZYDUSLIFE fundamental statistics | |
|---|---|
| Market cap | ₹953.51b |
| Earnings (TTM) | ₹42.78b |
| Revenue (TTM) | ₹214.84b |
22.3x
P/E Ratio4.4x
P/S RatioIs ZYDUSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYDUSLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹214.84b |
| Cost of Revenue | ₹63.03b |
| Gross Profit | ₹151.81b |
| Other Expenses | ₹109.03b |
| Earnings | ₹42.78b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 42.51 |
| Gross Margin | 70.66% |
| Net Profit Margin | 19.91% |
| Debt/Equity Ratio | 0.6% |
How did ZYDUSLIFE perform over the long term?
See historical performance and comparison